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Clear, transparent, and sufficiently detailed abstracts of conferences and journal articles
related to randomized controlled trials (RCTs) are important, because readers often base their
assessment of a trial solely on information in the abstract. Here, we extend the CONSORT
(Consolidated Standards of Reporting Trials) Statement to develop a minimum list of essential
items, which authors should consider when reporting the results of a RCT in any journal or
conference abstract.
Methods and Findings
We generated a list of items from existing quality assessment tools and empirical evidence. A
three-round, modified-Delphi process was used to select items. In all, 109 participants were
invited to participate in an electronic survey; the response rate was 61%. Survey results were
presented at a meeting of the CONSORT Group in Montebello, Canada, January 2007, involving
26 participants, including clinical trialists, statisticians, epidemiologists, and biomedical editors.
Checklist items were discussed for eligibility into the final checklist. The checklist was then
revised to ensure that it reflected discussions held during and subsequent to the meeting.
CONSORT for Abstracts recommends that abstracts relating to RCTs have a structured format.
Items should include details of trial objectives; trial design (e.g., method of allocation, blinding/
masking); trial participants (i.e., description, numbers randomized, and number analyzed);
interventions intended for each randomized group and their impact on primary efficacy
outcomes and harms; trial conclusions; trial registration name and number; and source of
funding. We recommend the checklist be used in conjunction with this explanatory document,
which includes examples of good reporting, rationale, and evidence, when available, for the
inclusion of each item.
Conclusions
CONSORT for Abstracts aims to improve reporting of abstracts of RCTs published in journal
articles and conference proceedings. It will help authors of abstracts of these trials provide the
detail and clarity needed by readers wishing to assess a trial’s validity and the applicability of its
results.
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PLoS MEDICINEIntroduction
Well-written abstracts of conferences and journal articles
reporting randomized controlled trials (RCTs) are important,
because readers will often base their initial assessment of a
trial on the information reported in an abstract. They may
then use this information to decide whether or not to seek
more knowledge about the trial, such as by reading the full
report if available. In some geographic areas, the abstract of a
RCT may be all that health professionals have easy access to,
and health-care decisions may be made solely on information
reported in it. Where the results of a trial are reported only as
a conference abstract, this abstract may provide the only
permanent information about a study and the only way that
its results can be accessed by most readers [1]. Journal and
conference abstracts should contain sufﬁcient information
about the trial to serve as an accurate record of its conduct
and ﬁndings, providing optimal information about the trial
within the space constraints of the abstract format. A
properly constructed and well-written abstract should also
help individuals to assess quickly the validity and applicability
of the ﬁndings and, in the case of abstracts of journal articles,
aid the retrieval of reports from electronic databases [2].
Conference abstracts, in particular, can provide valuable
information for systematic reviewers about studies that are
not otherwise published, the exclusion of which from the
review might introduce bias [3].
Incomplete and Inaccurate Reporting
A number of studies have highlighted the need for
improvements in the reporting of conference abstracts and
the abstracts of journal articles presenting the results of RCTs
[4]. There are concerns over the accuracy and quality of trial
reports published in the proceedings of scientiﬁc meetings,
including the lack of information about the trial and the
robustness of the trial results, compared with results
published in a journal article [5–9]. Research has also shown
that trial information reported in conference abstracts may
differ from that reported in subsequent full publications of
the same study [10–13].
The abstract of a journal article has similar limitations to
those of an abstract submitted to a scientiﬁc meeting. In
particular, print space limitations constrain the detail that
authors may include on the trial’s methodology and results. A
journal abstract should be an accurate reﬂection of what is
included in the full journal article and should not include
information that does not appear in the body of the paper.
Studies comparing the accuracy of information reported in a
journal abstract with that reported in the text of the full
publication have found claims that are inconsistent with, or
missing from, the body of the full article [14–18]. Conversely,
omitting important contrary results from the abstract, such as
those concerning side effects, could seriously mislead a
reader’s interpretation of the trial ﬁndings [19,20].
Improving the Reporting of Randomized Trials in Journal
and Conference Abstracts
The CONSORT (Consolidated Standards of Reporting
Trials) Statement, ﬁrst published in 1996 [21] and updated
in 2001 [22], provides recommendations for reporting RCTs
in health-care journals. CONSORT has been endorsed by the
World Association of Medical Editors (WAME), the Interna-
tional Committee of Medical Journal Editors (ICMJE), and the
Council of Science Editors (CSE). Currently, however, the
CONSORT Statement provides limited guidance about
preparing abstracts and, while it encourages the use of a
structured format, this is not a formal requirement. The
ICMJE Uniform Requirements [23] also provide only limited
guidance on the format of abstracts for journal articles.
We believe that instructions to authors from journals and
conference organizers should provide speciﬁc instructions
about key elements of a trial that should be reported in an
abstract. Indeed, a recent study examining the content of 35
journals’ instructions to authors found that only 4% of all
words were devoted to the content or format of the abstract
[24]. Without a minimum amount of key information on a
trial, it is difﬁcult to assess the validity of its results or its
applicability.
Methods
CONSORT for Abstracts: Development of the Checklist
In collaboration with others in the CONSORT Group, we
have extended the current CONSORT Statement to develop a
checklist of essential items that authors should consider when
reporting the main (i.e., those reporting the pre-speciﬁed
primary outcome) results of a RCT in any journal or
conference abstract.
First, we established a steering committee (MC, SH, DM,
PM, and EW). Second, we generated a list of items from
existing quality assessment and reporting tools, including the
CONSORT Statement [22] and other guidance for the
structured reporting of journal abstracts and short reports
[25–28]. Third, additional items were generated as part of an
empirical study assessing the quality of trials reported in
conference proceedings and journal abstracts [29].
We then used a modiﬁed Delphi consensus method [30] to
select and reduce the number of possible checklist items. A
total of 109 participants, who were known to have an interest
in the reporting of RCTs, the structure of abstracts, or both
were invited (by e-mail) to participate in a Web-based survey
and rate the importance of 27 suggested checklist items. The
response rate was 61% (n ¼ 63) for the ﬁrst round of the
Delphi survey. Respondents included journal editors (13%),
health-care professionals (22%), methodologists (40%), sta-
tisticians (5%), trialists (7%), and other individuals with
expertise in the reporting of RCTs (13%). During three
rounds of the survey, participants were asked about their
views on the relative importance of the possible checklist
items. A more detailed discussion of the Delphi process is
included in Text S1.
The results of the survey were presented at a one-day
meeting (part of a three-day CONSORT Group meeting) in
January 2007, in Montebello, Canada, attended by 26
participants, several of whom also participated in the Delphi
survey. The meeting began with a review of the checklist
items proposed as a result of the Delphi process. Participants
then discussed in small groups whether proposed checklist
items should be included, excluded, or modiﬁed in the ﬁnal
checklist. These small-group deliberations were further
discussed during plenary sessions.
Following the meeting, the checklist was revised and
circulated to the steering committee and meeting partic-
ipants to ensure that it reﬂected the discussions. The steering
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document, which was circulated through several iterations
among the authors.
CONSORT for Abstracts Checklist: Explanation and
Elaboration
We developed this document using the template used to
develop the CONSORT and STARD (Standards for Reporting
Diagnostic Accuracy) explanatory articles [31,32]. Here each
item (see Table 1) is stated, a recent example of good
reporting of the item is provided, followed by an explanation
that includes the rationale and scientiﬁc background and,
where possible, discusses the evidence for the item as it
relates to a trial reported in a journal or conference abstract.
Checklist Items
TITLE
Item: Identification of the study as randomized.
Example. ‘‘Effectiveness of a strategy to improve adherence
to tuberculosis treatment in a resource poor setting: a cluster
randomized trial’’ [33].
Explanation. The ability to identify a relevant report in an
electronic database depends to a large extent on how it was
indexed. Indexers may not classify a report as a RCT if the
authors do not explicitly report this information [34]. To help
ensure that a study is appropriately indexed and identiﬁed as
a RCT, authors should state explicitly in the title that the
participants were randomly assigned to their comparison
groups.
AUTHORS
Item: Contact details for the corresponding author.
(This item is speciﬁc to conference abstracts)
Example. ‘‘Correspondence to: Dr Sally Hopewell, UK
Cochrane Centre, Summertown Pavilion, Middle Way, Ox-
ford OX2 7LG, UK. Tel: þ44 1865 516300; Fax: þ44 1865
516311; Email: shopewell@cochrane.co.uk.’’
Explanation. Adequate contact details for the correspond-
ing author are particularly important for RCTs reported in
conference proceedings. These abstracts may be the only
lasting source of information for many trials, as only half of
RCTs reported in conference proceedings are subsequently
published in full [1]. Adequate contact information would
enable readers to contact trialists for additional information
or clariﬁcations regarding reported data. Adequate contact
details should include the telephone number, postal, and
email address of the principal investigator and, if available,
the trial Web site.
TRIAL DESIGN
Item: Description of the trial design.
Example. ‘‘A cluster randomized controlled trial...’’ [33].
Explanation. The design of the trial should be described,
for example, parallel group, cluster randomized, crossover,
factorial, superiority, equivalence or noninferiority, or some
other combination of these designs. An important reason for
identifying the design of the trial is to ensure appropriate
indexing in electronic databases, thus ensuring greater ease
of identiﬁcation [34]. Alerting readers to the design of the
trial also provides transparency as to the type of design used
to conduct the trial and should reduce the likelihood of
inadvertently misinterpreting data. For example, in a report
of a cluster trial, readers might misinterpret a small sample
size as the number of participants rather than the number of
clusters, or vice versa [35].
METHODS
Participants
Item: Eligibility criteria for participants and the settings
where the data were collected.
Example. ‘‘... conducted between June 2003 and January
2005, at 16 government district health centers in Senegal.
Patients older than 15 years with newly diagnosed sputum
smear-positive pulmonary TB were randomly assigned to the
intervention or control group’’ [33].
Explanation. Every RCT addresses an issue relevant to a
particular population or group with the condition of interest.
Trialists may further restrict this sample by using eligibility
criteria and by performing the trial in a particular setting (for
example primary, secondary, or tertiary care). Participant
eligibility criteria may relate to demographics, clinical
diagnosis, and comorbid conditions. A clear description of
the trial participants and setting in which they were studied is
needed so that readers may assess the external validity
(generalisability) of the trial and determine its applicability to
their own setting.
Interventions
Item: Interventions intended for each group.
Example. ‘‘Patients were randomized to receive either 100
mg hydrocortisone or matching placebo as follows: the ﬁrst
dose in the evening of the operative day, then 1 dose every 8
hours during the next 3 days. In addition, all patients received
oral metoprolol (50–150 mg/d) titrated to heart rate’’ [36].
Explanation. The essential features of the experimental
and comparison interventions should be described. Authors
should report details about the interventions, e.g., dose, route
of administration, duration of administration, surgical
procedure, or manufacturer of inserted device.
Objective
Item: Specific objective or hypothesis.
Example. ‘‘To compare the effectiveness of an early switch
to oral antibiotics with the standard 7 day course of
intravenous antibiotics in severe community acquired pneu-
monia’’ [37].
Explanation. The abstract should provide a clear statement
of the speciﬁc objective or hypothesis addressed in the trial. If
more than one objective is addressed, the main objective (i.e.,
based on the prespeciﬁed primary outcome) should be
indicated and only key secondary objectives stated [26].
Outcome
Item: Clearly defined primary outcome for this report.
Example. ‘‘Main outcome measure: all-cause mortality at
180 days’’ [38].
Explanation. RCTs assess outcomes for which the inter-
ventions are being compared. Most trials have several
outcomes, some of which are deemed more important than
others. Such rankings are typically reported as primary and
secondary outcomes. There is evidence of selective reporting
with signiﬁcant or favourable outcomes being more likely to
be published than nonsigniﬁcant outcomes [39–41].
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trial and when it was assessed (e.g., the time frame over which
it was measured). The primary outcome is the prespeciﬁed
outcome considered of greatest importance and is usually the
one used in the sample size calculation [22]. In some instances
a publication may report an outcome different from the
primary outcome. For example, conference abstracts are
more likely to report interim analyses than are full
publications [8,10], or to present different results for a single
trial in a series of abstracts. If the abstract focuses on a
secondary outcome of a trial, the abstract should identify
both this outcome and the primary outcome of the trial.
Randomization
Item: How participants were allocated to interventions.
Example. ‘‘Randomization was computer-generated, with
allocation concealment by opaque sequentially numbered
sealed envelopes’’ [42].
Explanation. It is important to conceal the allocation
sequence from those assigning participants to the interven-
tion groups. Allocation concealment prevents investigators
from inﬂuencing which participants are assigned to a given
intervention group (i.e., selection bias). Evidence shows that
reports of trials reporting inadequate allocation concealment
are associated with exaggerated treatment effects [43,44].
Research suggests that adequate allocation concealment is
more important in preventing selection bias than are other
components of the randomization process, such as the
sequence generation (e.g., use of computer or random
number table) [45].
Authors should clearly describe the method for assigning
participants to interventions. Examples of approaches used
to ensure adequate concealment include: centralised (e.g.,
allocation by a central ofﬁce) or pharmacy-controlled
randomization; sequentially numbered identical containers
that are administered serially to participants; on-site com-
puter system combined with allocations kept in a locked,
unreadable computer ﬁle that investigators can access only
after the characteristics of an enrolled participant are
entered; and sequentially numbered, opaque sealed envelopes
[46].
The method of allocation concealment is generally poorly
reported in conference abstracts and in abstracts of journal
articles [7,47–49]. For example, in a review of 494 abstracts
presented at an oncology conference in 1992 and 2002, only
nine (2%) abstracts reported the method of allocation
concealment. This information was missing from the remain-
ing 485 conference abstracts, with no improvements seen
over the ten-year period [7].
Blinding (Masking)
Item: Whether or not participants, caregivers, and those
assessing the outcomes were blinded to group
assignment.
Example. ‘‘Children, parents, and the research assistants
were blinded to group assignment’’ [50].
Explanation. Blinding refers to the practice of keeping the
trial participants, care providers, data collectors, and some-
times those analysing the data, unaware of which intervention
is being administered to which participant, so that they will
not be inﬂuenced by that knowledge. The term masking is
sometimes used instead of blinding [51,52] and might be
preferable when reporting studies involving eyes and vision.
It is important that authors describe whether or not
participants, those administering the intervention (usually
health-care providers), and those assessing the outcome (the
data collectors and analysts) were blinded to the group
Table 1. Items to Include when Reporting a Randomized Trial in a Journal or Conference Abstract
Item Description
Title Identification of the study as randomized
Authors * Contact details for the corresponding author
Trial design Description of the trial design (e.g. parallel, cluster, non-inferiority)
Methods
Participants Eligibility criteria for participants and the settings where the data were
collected
Interventions Interventions intended for each group
Objective Specific objective or hypothesis
Outcome Clearly defined primary outcome for this report
Randomization How participants were allocated to interventions
Blinding (masking) Whether or not participants, care givers, and those assessing the outcomes
were blinded to group assignment
Results
Numbers randomized Number of participants randomized to each group
Recruitment Trial status
Numbers analysed Number of participants analysed in each group
Outcome For the primary outcome, a result for each group and the estimated effect size
and its precision
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
*This item is specific to conference abstracts.
doi:10.1371/journal.pmed.0050020.t001
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CONSORT for Abstractsallocation. Authors should avoid using terms such as ‘‘single’’
or ‘‘double’’ blind as such terms are not well-understood [53].
Information on the method of blinding is poorly reported
in conference and journal abstracts [7,8,47–49]. Such report-
ing is valuable as blinding may be important in protecting
against bias [51]. Studies have shown that if investigators are
aware of the treatment, their attitudes for or against an
intervention can directly affect whether or not they include,
or treat, participants in a trial [45]. Furthermore, there is
evidence that participants who are aware of their assignment
status are more likely to report symptoms, leading to biased
results [51]. Perhaps most importantly, if outcome assessors
are not blinded to the intervention they are more likely to
report favourable outcomes for the intervention which they
believe is better [54]. However, unlike allocation conceal-
ment, blinding of the participants, health-care providers, and
outcome assessors may not always be appropriate or possible,
such as in many surgical trials. In this case, authors should




Item: Number of participants randomized to each group.
Example. ‘‘Children (n ¼ 633) aged 1–3 randomly allocated
to receive fortiﬁed milk (n ¼ 316) or control milk (n ¼ 317)’’
[55].
Explanation. The number of participants randomized to
each intervention group is an essential element of the results
of a trial. This number deﬁnes the sample size, and readers
can use it to assess whether all randomized participants were
included in the data analysis. Again, this may be particularly
important for conference abstracts reporting interim analy-
ses, if a trial is still open to participant accrual or follow-up
[8,10]. Here authors should report the period of recruitment
on which the data are based.
Recruitment
Item: Trial status.
Example. ‘‘An interim analysis was performed because of
slow accrual’’ [56].
Explanation. Authors should describe the status of the trial
and whether it is still ongoing, closed to recruitment, or
closed to follow-up. This information is particularly impor-
tant for conference abstracts, which are more likely than full
articles to report interim analyses [10].
If the trial has stopped earlier than planned it is important
to say why. Possible reasons for early termination include:
slow accrual rates, poor data quality, poor adherence,
resource deﬁciencies, unacceptable harms or large beneﬁts,
or emerging information that makes the trial irrelevant,
unnecessary, or unethical. If a trial stops early for apparent
beneﬁt, the estimates of treatment effect are more likely to be
biased and prone to exaggeration [57,58].
Numbers Analysed
Item: Number of participants analysed in each group.
Example. ‘‘... 300 were included in the analysis of the
primary outcome (100 in the acetaminophen group, 100 in
the ibuprofen group, and 100 in the codeine group)’’ [50].
Explanation. Authors should report the number of
participants included in the analysis for each intervention
group. These data permit an assessment of whether partic-
ipants were analysed according to their original group
assignment, which is important, because failure to include
all participants in the analysis may bias the results of the trial
[22].
Several studies have reported deﬁciencies in journal and
conference abstracts in reporting the number of participants
included in the analysis [6–8,13,48,59]. In a review of RCTs in
acute brain injury reported in journal abstracts, only 43%
reported the number of participants included in the analysis
[48]. In another evaluation of trials reported in abstracts for
an oncology conference, only 40% reported the number of
participants analysed, and only 6% indicated intention to
treat analysis [8].
Outcome
Item: For the primary outcome, a result for each group
and the estimated effect size and its precision.
Example. ‘‘Treatment was successful for 682 (88%) of 778
patients recruited in the intervention group, and for 563
(76%) of 744 patients recruited in the control group (adjusted
risk ratio [RR], 1.18; 95% conﬁdence interval [CI], 1.03–1.34)’’
[33].
Explanation. For the primary outcome, authors should
report trial results as a summary of the outcome in each
group (e.g., the number of participants with or without the
event, or the mean and standard deviation of measurements),
together with the contrast between groups known as the
effect size. For binary outcomes, the effect size could be the
relative risk, relative risk reduction, odds ratio, or risk
difference. For survival time data, the measurement could
be the hazard ratio or difference in median survival time. For
continuous data, the effect measure is usually the difference
in means. Authors should present conﬁdence intervals for the
contrast between groups and as a measure of the precision
(uncertainty) of the estimate of the effect [22]. For abstracts
not reporting the ‘‘primary’’ outcome of the trial (e.g.,
abstracts focusing on safety data or economic impacts), the
secondary nature of the outcomes should be indicated, and,
where possible, sufﬁcient details of the primary outcome
should be included to allow other ﬁndings to be taken in the
proper context.
Several studies have observed deﬁciencies in the reporting
of statistical results in journal abstracts [57,60–62]. For
example, Pocock and colleagues [57] found that journal
abstracts of RCTs tended to overemphasize statistically
signiﬁcant outcomes compared to the full journal article,
leading to problems in interpretation of the results. Poor
reporting of results is also a problem for trials presented in
conference abstracts [7,8,59]. A study of 494 reports of RCTs
in oncology found that only 26% of conference abstracts
reported the size of the effect and signiﬁcance of the result
[7].
Harms
Item: Important adverse events or side effects.
Example. ‘‘Adverse events were more common with top-
iramate vs placebo, respectively, including paresthesia (50.8%
vs 10.6%), taste perversion (23.0% vs 4.8%), anorexia (19.7%
vs 6.9%), and difﬁculty with concentration (14.8% vs 3.2%)’’
[63].
Explanation. Most interventions have unintended and
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effects. In order to make rational and balanced decisions,
readers need information about the relative beneﬁts and
harms of an intervention. Authors should describe any
important adverse (or unexpected) effects of an intervention
in the abstract. If no important adverse events have occurred,
the authors should state this explicitly [20].
Explicit reference to the reporting of harms in the title or
abstract is also important for appropriate database indexing
and information retrieval. Derry and colleagues [64] found
that only 66 of 107 RCTs that reported data on adverse events
in the full publication mentioned harms in the title or
abstract; thus, harms could not have been identiﬁed for many
of the articles in a search of titles and abstracts in an
electronic bibliographic database.
Harms are also poorly reported in conference abstracts. A
recent examination of over 800 ophthalmology conference
abstracts reporting trials found that the majority (71%) did
not report harms related to the treatment intervention, and
harms were reported as a primary outcome measure in only
6% of abstracts [9].
CONCLUSIONS
Item: General interpretation of the results.
Example. ‘‘Multivitamin supplementation reduced the
incidence of low birth weight and small-for-gestational-age
births but had no signiﬁcant effects on prematurity or fetal
death’’ [65].
Explanation. The conclusions of the trial, consistent with
the results reported in the abstract, should be clearly stated
along with their clinical application (avoiding over-general-
isation). Authors should balance the beneﬁts and harms in
their conclusions. Where applicable, authors should also note
whether additional studies are required before the results are
used in clinical settings [26].
TRIAL REGISTRATION
Item: Registration number and name of trial register.
Example. ‘‘Trial Registry: www.clinicaltrials.gov; Identiﬁer:
NCT00412009’’ [33].
Explanation. Nonpublication of entire trials and selective
reporting of outcomes within trials has been well-docu-
mented [39,41,66]. Covert redundant publication can also
cause problems in systematic reviews when results from the
same trial are inadvertently included more than once [67]. To
minimize or avoid these problems there have been many calls
for trial registration [68]. Due to more recent serious
problems of withholding data [69] there has been a renewed
effort to register RCTs. By registering a RCT, authors
typically report a minimal set of information and obtain a
unique trial registration number.
In September 2004 the International Committee of Medical
Journal Editors (ICMJE) indicated a change in their policy for
publishing RCTs, saying that they would consider trials for
publication only if they had been registered before the
enrolment of the ﬁrst patient (as of 1 July 2005) [70]. This
position has resulted in a dramatic increase in the number of
trials being registered [71].
In an abstract reporting a trial, authors should provide
details of the trial registration number and name of trial
register. Registration information will be particularly impor-
tant for abstracts reported in conference meetings, as not all
of them are subsequently published [1]. Such trial registration
provides readers with a way to obtain more information
about the trial and its results. Registration information will
also help to link abstracts with subsequent full publications
(or multiple abstracts from the same trial) and thus reduce
the risk of inadvertent double-counting in systematic reviews.
FUNDING
Item: Source of funding.
Example. ‘‘Funded by The Breast Cancer Research Foun-
dation’’ [72].
Explanation. Authors should report the source of funding
for the trial as this is important information for readers
assessing a trial. A recent systematic review showed that
studies funded by the pharmaceutical industry had four times
(odds ratio 4.05; 95% conﬁdence interval 2.98–5.51) the odds
of having outcomes favouring the sponsor than studies
funded by other sources [73]. Similarly, authors should report
any other sources of support, such as in the preparation of
the abstract, presentation, or manuscript [74].
Discussion
CONSORT for Abstracts strongly recommends the use of
structured abstracts for reporting RCTs [75]; the full
CONSORT Statement also supports their use [22]. Since
1987 when the Ad Hoc Working Group for Critical Appraisal
of the Medical Literature [25–27] ﬁrst published recommen-
dations for the adoption of structured abstracts, many
journals have promoted their use, and many different formats
for structured abstracts now exist. We recognise that journals
may have developed their own set of headings for abstracts
[76,77]. It is not the intention of this reporting guide to
suggest changes to these headings but to recommend what
information should be reported within them when describing
a RCT.
It is important to note that, because of the space
limitations of an abstract, it will only ever be possible to
provide limited information about a trial report. CONSORT
for Abstracts sets out to recommend what information should
be reported within these constraints when describing a RCT.
Readers of abstracts should always try to obtain more
information about a trial and its results, either by accessing
the full publication or, in the case of unpublished conference
abstracts [1], by contacting the authors for more information.
With the aim of greatly improving access to information
about clinical trials and their results, the World Health
Organization (WHO) recently established an International
Clinical Trials Registry Platform. Their goal is to produce a
single minimum standard for information that trialists should
disclose before the trial begins [78,79]. Moreover, as registra-
tion of the trial methods has become more common, several
forces have begun to advocate for the disclosure of trial
results in specially designed repositories linked to trial
registers. In June 2007, endorsing the WHO’s International
Clinical Trials Registry Platform, the ICMJE published an
editorial recommending a standard abstract format for
reporting results. The ICMJE suggested that CONSORT for
Abstracts may be one such option [80]. At present, there is no
formal consensus on international norms and standards for
results reporting. The WHO International Clinical Trials
Registry Platform has therefore established a Study Group on
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WHO Registry Platform on matters related to the reporting
of the ﬁndings of clinical trials. Full transparency and
accountability require that all results of all trials are made
available to the public in a timely manner.
Like the CONSORT Statement, CONSORT for Abstracts
has been developed primarily for reporting the main results
of parallel group RCTs (i.e., those relating to the prespeciﬁed
primary outcome). There may well be instances where
different types of trial information, such as composite
outcomes, or different designs, such as cluster trials or
noninferiority and equivalence trials, will require additional
information not covered in this explanation and elaboration
document. Possible additional abstract extensions may be
warranted, as has been done for the CONSORT Statement for
full reports [35,81].
The length of an abstract reporting a RCT using the
CONSORT for Abstracts checklist is difﬁcult to estimate. In
developing the checklist 250 to 300 words were found to be
sufﬁcient to address all of the items in the checklist. Worked
examples of using the CONSORT for Abstracts checklist are
available on the CONSORT website at http://www.
consort-statement.org/. In the past, MEDLINE has truncated
journal abstracts at 250 words [82]. This has resulted in many
journals setting word limits for abstracts in their journals at
250 words. However, since 2000 the National Library of
Medicine increased the word limit for an abstract appearing
in MEDLINE to 10,000 characters, which equates to over
1,000 words. While most abstract reports will not require
anywhere near 1,000 words, such a word length will be
sufﬁcient to report even the most complex of trials in
abstract form [82].
Clear, transparent, and accurate reporting of research is
important because it enables readers to understand what was
done and hence to evaluate the reliability and relevance of
the ﬁndings. This extension of the CONSORT Statement aims
to improve the reporting of RCTs in both the abstracts of
journal articles and conference proceedings [83]. When using
the CONSORT for Abstracts checklist we encourage authors
to use it in conjunction with this explanation and elaboration
document. We encourage journals and conference organisers
to endorse the use of CONSORT for Abstracts by modifying
their ‘‘Instructions to Authors’’ and drawing their readers’
attention to this reporting guidance, perhaps through an
editorial or by including a link to the checklist on the
conference website. The most important beneﬁt will be to
enable readers to use abstracts more effectively and to assess
the validity of the research more precisely. When key aspects
of study methods are omitted, reader assessments are less
certain, and might well take longer to make.
Supporting Information
Text S1. Results of the Delphi Consensus Survey
Found at doi:10.1371/journal.pmed.0050020.sd001 (69 KB RTF).
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